VBI Vaccines Inc. (T:VBV)

Business Focus: Biotechnology & Medical Research (NEC)

Get the company report for the most recent outlook updated daily

Mar 12, 2018 04:15 pm ET

VBI Vaccines Announces Voluntary Delisting from the Toronto Stock Exchange

CAMBRIDGE, Mass., March 12, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. ("VBI" or the "Company") (Nasdaq:VBIV) (TSX:VBV), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that it has applied to voluntarily delist its...

Jan 26, 2018 04:15 pm ET

VBI Vaccines Announces Changes to its Board of Directors

CAMBRIDGE, Mass., Jan. 26, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) (TSX:VBV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced two changes to its Board of Directors effective January 23, 2018...

Jan 17, 2018 08:00 am ET

VBI Vaccines Announces Dosing of First GBM Patient in Phase 1/2a Clinical Study of VBI-1901

CAMBRIDGE, Mass., Jan. 17, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) (TSX:VBV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that the first patient has been dosed in a Phase 1/2a...

Dec 19, 2017 08:00 am ET

VBI Vaccines Announces Initiation of Phase 3 Clinical Program for Sci-B-Vac® Hepatitis B Vaccine

CAMBRIDGE, Mass., Dec. 19, 2017 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) (TSX:VBV) (“VBI”) announced today the initiation of the global Phase 3 clinical program for Sci-B-Vac®, its third-generation hepatitis B vaccine, with the commencement of patient dosing...

Dec 12, 2017 08:00 am ET

VBI Vaccines to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference

CAMBRIDGE, Mass., Dec. 12, 2017 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) (TSX:VBV) (VBI) today announced that Jeff Baxter, President and CEO, will present at the BMO Capital Markets Prescriptions for Success Healthcare Conference on Thursday, December 14,...

Nov 10, 2017 08:00 am ET

VBI Vaccines to Present New Preclinical Data for its GBM Immunotherapy, VBI-1901, at SITC 2017

CAMBRIDGE, Mass., Nov. 10, 2017 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) (TSX:VBV) (VBI) today announced that Catalina Soare, VBI’s head of preclinical development, will present new preclinical data demonstrating the potency of VBI-1901 as a therapeutic vaccine...

Nov 02, 2017 08:00 am ET

VBI Vaccines Strengthens Board of Directors with Appointment of Ran Nussbaum

CAMBRIDGE, Mass., Nov. 02, 2017 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) (TSX:VBV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the appointment, effective October 30, 2017, of Ran Nussbaum, co-founder and...

Oct 25, 2017 04:01 pm ET

VBI Vaccines Announces Proposed Concurrent Public Offering and Registered Direct Offering of Common Shares

CAMBRIDGE, Mass., Oct. 25, 2017 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) (TSX:VBV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that it has commenced concurrently an underwritten public offering and a registered direct offering of its common shares. VBI also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of common shares offered in the public offering. Both offerings are subject to market and other conditions and there can be no ...

Oct 17, 2017 08:00 am ET

VBI Vaccines Hepatitis B Data Selected as Presidential Poster of Distinction at The Liver Meeting(R) 2017

VBI Vaccines Inc. (NASDAQ: VBIV)(TSX: VBV) (VBI) today announced the company's abstract, "Antibody and Cell-mediated Immunity against PreS1, PreS2, and S Antigens after Immunizations with a Third Generation Hepatitis B Vaccine," has been selected as a Presidential Poster of Distinction for presentation at the 68th annual meeting of the American Association for the Study of Liver Diseases (AASLD), The Liver Meeting(R) 2017, in Washington D.C. on October 23, 2017.

Oct 17, 2017 07:58 am ET

VBI Vaccines Hepatitis B Data Selected as Presidential Poster of Distinction at The Liver Meeting(R) 2017

Oct 11, 2017 08:00 am ET

VBI Vaccines to Present at The World Vaccine Congress Europe 2017 in Barcelona

VBI Vaccines Inc. (NASDAQ: VBIV)(TSX: VBV) (VBI) today announced that Adam Buckley, vice president of business development, will discuss VBI's enveloped virus-like particle (eVLP) platform, highlighting data from two of the company's vaccine programs, during a presentation at the World Vaccine Congress Europe held Oct. 10-12, 2017, in Barcelona.

Sep 12, 2017 08:00 am ET

VBI Vaccines to Present at September 2017 Investor Conferences

VBI Vaccines Inc. (NASDAQ: VBIV)(TSX: VBV) (VBI) today announced that Jeff Baxter, President and CEO, will provide a corporate overview and update at two investor conferences in September.

Sep 12, 2017 07:58 am ET

VBI Vaccines to Present at September 2017 Investor Conferences

VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) (VBI) today announced that Jeff Baxter, President and CEO, will provide a corporate overview and update at two investor conferences in September. VBI will present at the...

Aug 30, 2017 08:00 am ET

VBI Vaccines Announces FDA Acceptance of Investigational New Drug Application for Sci-B-Vac(R) Phase 3 Clinical Program

Aug 30, 2017 07:58 am ET

VBI Vaccines Announces FDA Acceptance of Investigational New Drug Application for Sci-B-Vac(R) Phase 3 Clinical Program

Sci-B-Vac® is a third-generation hepatitis B vaccine, approved for use in Israel and 14 other countries VBI expects to initiate enrollment in a Phase 3 clinical program later in the second half of 2017 in the U.S., Europe and...

Aug 28, 2017 08:30 am ET

VBI Vaccines to Present New Preclinical Data for its GBM Immunotherapy, VBI-1901, at The Immuno-Oncology Summit

VBI Vaccines Inc. (NASDAQ: VBIV)(TSX: VBV) (VBI) today announced that David Anderson, Ph.D., Chief Scientific Officer of VBI, will present new preclinical data demonstrating the mechanism by which VBI-1901 stimulates CMV-specific immunity in monkeys at The Immuno-Oncology Summit in Boston on Wednesday, Aug. 30, 2017. VBI-1901 is a novel immunotherapy developed using VBI's eVLP technology to target CMV-positive (CMV+) tumors, including glioblastoma multiforme (GBM), the company's lead immuno-oncology program.

Aug 28, 2017 08:28 am ET

VBI Vaccines to Present New Preclinical Data for its GBM Immunotherapy, VBI-1901, at The Immuno-Oncology Summit

Aug 15, 2017 08:30 am ET

VBI Vaccines Announces FDA Acceptance of Investigational New Drug Application for VBI-1901 to Treat Glioblastoma Multiforme

VBI Vaccines Inc. (NASDAQ: VBIV) (TSX: VBV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's Investigational New Drug Application (IND) for VBI-1901, a novel immunotherapy targeting Glioblastoma Multiforme (GBM), one of the most common and aggressive malignant primary brain tumors in humans. The IND enables VBI to initiate a multi-center Phase I/2a clinical study evaluating VBI-1901 in patients with recurrent GBM in the

Aug 15, 2017 08:28 am ET

VBI Vaccines Announces FDA Acceptance of Investigational New Drug Application for VBI-1901 to Treat Glioblastoma Multiforme

Jul 27, 2017 07:30 am ET

VBI Vaccines Announces Positive Interim Data from Phase 1 Study of Preventative CMV Vaccine

VBI Vaccines Inc. (NASDAQ: VBIV)(TSX: VBV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced positive results from a planned, interim data read-out from a Phase 1 study of its preventative cytomegalovirus (CMV) vaccine.

Jul 27, 2017 07:28 am ET

VBI Vaccines Announces Positive Interim Data from Phase 1 Study of Preventative CMV Vaccine

Jul 11, 2017 04:05 pm ET

VBI Vaccines Announces Phase 3 Clinical Program for Sci-B-Vac(TM) Hepatitis B Vaccine

VBI Vaccines Inc. (NASDAQ: VBIV)(TSX: VBV) ("VBI") announced today its plans for a global Phase 3 clinical program for Sci-B-Vac(TM), its third-generation hepatitis B vaccine, following positive discussions with the U.S. Food & Drug Administration (FDA), the European Medicines Agency (EMA), and Health Canada.

Jul 11, 2017 04:03 pm ET

VBI Vaccines Announces Phase 3 Clinical Program for Sci-B-Vac(TM) Hepatitis B Vaccine

VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) ("VBI") announced today its plans for a global Phase 3 clinical program for Sci-B-Vac™, its third-generation hepatitis B vaccine, following positive discussions with the U.S. Food & Drug...

Jun 28, 2017 05:00 pm ET

VBI Vaccines Announces Results of Annual General and Special Meeting

VBI Vaccines Inc. (NASDAQ: VBIV)(TSX: VBV) ("VBI") today announced the voting results from its annual general and special meeting (the "Meeting") held on June 22, 2017.

Jun 28, 2017 04:58 pm ET

VBI Vaccines Announces Results of Annual General and Special Meeting

VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) ("VBI") today announced the voting results from its annual general and special meeting (the "Meeting") held on June 22, 2017. 30,823,557 common shares were represented at the Meeting, totaling 76.94%...

Jun 26, 2017 08:30 am ET

VBI Vaccines Added to Russell 2000® and Russell 3000® Indexes

VBI Vaccines, Inc. (NASDAQ: VBIV)(TSX: VBV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, announced today that it has been added to the Russell 2000(R) and the Russell 3000(R) Indexes following the annual reconstitution, which took effect after the US market closed on Friday, June 23rd.

Jun 26, 2017 08:28 am ET

VBI Vaccines Added to Russell 2000® and Russell 3000® Indexes

Jun 19, 2017 08:30 am ET

VBI Vaccines Reports Positive Outcome from Phase III Pre-IND Discussions with the FDA for Hepatitis B Vaccine, Sci-B-Vac(TM)

VBI Vaccines Inc. (NASDAQ: VBIV)(TSX: VBV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, announced today that it has completed a pre-Investigational New Drug ("IND") meeting with the U.S. Food and Drug Administration ("FDA") to discuss the Phase III clinical program for Sci-B-Vac(TM), VBI's third-generation hepatitis B vaccine. Sci-B-Vac(TM) is currently approved for use in Israel and 14 other countries worldwide.

Jun 19, 2017 08:28 am ET

VBI Vaccines Reports Positive Outcome from Phase III Pre-IND Discussions with the FDA for Hepatitis B Vaccine, Sci-B-Vac(TM)

Jun 05, 2017 08:30 am ET

VBI Vaccines to Present at Jefferies 2017 Global Healthcare Conference

VBI Vaccines Inc. (NASDAQ: VBIV)(TSX: VBV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that Jeff Baxter, VBI's President and CEO, will present at the Jefferies 2017 Global Healthcare Conference on Friday, June 9, 2017 at 12:30 PM ET in New York City.

Jun 05, 2017 08:28 am ET

VBI Vaccines to Present at Jefferies 2017 Global Healthcare Conference

May 02, 2017 08:30 am ET

VBI Vaccines Provides Update on its Congenital CMV Phase I Clinical Study

VBI Vaccines Inc. (NASDAQ: VBIV) (TSX: VBV) ("VBI") today provided an update on its cytomegalovirus ("CMV") Phase I clinical study, which is assessing the safety and tolerability of VBI's vaccine candidate to prevent congenital CMV infection. Congenital CMV infection is a leading cause of birth defects, affecting more live births than Down syndrome or fetal alcohol syndrome, making it a key public health priority.

May 02, 2017 08:28 am ET

VBI Vaccines Provides Update on its Congenital CMV Phase I Clinical Study

Apr 05, 2017 08:30 am ET

VBI Vaccines to Present Updates on Multiple Programs at the World Vaccine Congress

VBI Vaccines Inc. (NASDAQ: VBIV)(TSX: VBV) ("VBI") is scheduled to present updates on two of its programs at the World Vaccine Congress on Tuesday, April 11, 2017 at 3:40 PM ET and 4:40 PM ET. The event is being held at the Grand Hyatt in Washington, D.C.

Apr 05, 2017 08:28 am ET

VBI Vaccines to Present Updates on Multiple Programs at the World Vaccine Congress

VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) ("VBI") is scheduled to present updates on two of its programs at the World Vaccine Congress on Tuesday, April 11, 2017 at 3:40 PM ET and 4:40 PM ET. The event is being held at the Grand Hyatt in...

Mar 30, 2017 08:30 am ET

VBI Vaccines Appoints Avi Mazaltov as Global Head of Manufacturing and SciVac General Manager; Rehovot, Israel Site

VBI Vaccines Inc. (NASDAQ: VBIV)(TSX: VBV) ("VBI") and SciVac Ltd. ("SciVac"), a wholly owned subsidiary of VBI, are pleased to announce the appointment of Avi Mazaltov as the Global Head of Manufacturing and General Manager of the SciVac manufacturing site in Rehovot, Israel.

Mar 30, 2017 08:28 am ET

VBI Vaccines Appoints Avi Mazaltov as Global Head of Manufacturing and SciVac General Manager; Rehovot, Israel Site

VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) ("VBI") and SciVac Ltd. ("SciVac"), a wholly owned subsidiary of VBI, are pleased to announce the appointment of Avi Mazaltov as the Global Head of Manufacturing and General Manager of the SciVac...

Feb 22, 2017 08:30 am ET

VBI Vaccines Receives Positive Response from Health Canada's Initial Evaluation of the Proposed Sci-B-Vac Phase III Clinical Program

VBI Vaccines Inc. (NASDAQ: VBIV)(TSX: VBV) ("VBI") announced today that the Biologics and Genetic Therapies Directorate (BGTD) of Health Canada expressed its general support and acceptance of the company's development path for its Sci-B-Vac(TM) vaccine, a prophylactic vaccine against hepatitis B, in a pre-Clinical Trial Application ("CTA") meeting. A complete CTA must be filed with and approved by BGTD, and all conditions of BGTD must be met, prior to the initiation of a clinical program in Canada.

Feb 22, 2017 08:28 am ET

VBI Vaccines Receives Positive Response from Health Canada's Initial Evaluation of the Proposed Sci-B-Vac Phase III Clinical Program

Feb 07, 2017 08:30 am ET

VBI Vaccines Receives Positive EMA Scientific Advice Regarding Sci-B-Vac(TM) Phase III Clinical Study

VBI Vaccines Inc. (NASDAQ: VBIV) (TSX: VBV) ("VBI") announced today the receipt of positive Scientific Advice from the Committee for Medicinal Products for Human Use (CHMP) of the European Medical Agency (EMA) regarding the company's development path for its Sci-B-Vac(TM) vaccine in Europe. Sci-B-Vac(TM) is a third-generation hepatitis B vaccine with demonstrated safety and efficacy in over 300,000 patients in currently licensed markets.

Feb 07, 2017 08:28 am ET

VBI Vaccines Receives Positive EMA Scientific Advice Regarding Sci-B-Vac(TM) Phase III Clinical Study

Dec 06, 2016 08:30 am ET

VBI Vaccines Closes $23.6 Million Financing from Perceptive Advisors

VBI Vaccines Inc. (NASDAQ: VBIV) (TSX: VBV) ("VBI"), a clinical-stage biopharmaceutical company developing infectious disease and immuno-oncology vaccines, today announced that it has raised $23.6 million in concurrent equity and debt financing transactions with Perceptive Advisors.

Dec 06, 2016 08:28 am ET

VBI Vaccines Closes $23.6 Million Financing from Perceptive Advisors

VBI Vaccines Inc. (NASDAQ:VBIV) (TSX:VBV) ("VBI"), a clinical-stage biopharmaceutical company developing infectious disease and immuno-oncology vaccines, today announced that it has raised $23.6 million in concurrent equity and debt financing...

Nov 14, 2016 08:30 am ET

VBI Vaccines Reports Rapid Seroprotection Results from an Interim Analysis of a Phase IV Postmarketing Study of its Sci-B-Vac(TM) Hepatitis B Vaccine

VBI Vaccines Inc. (NASDAQ: VBIV)(TSX: VBV) ("VBI") today reported interim results from an ongoing Phase IV postmarketing study to evaluate Sci-B-Vac(TM), VBI's licensed third-generation hepatitis B vaccine, in healthy adults.

Nov 14, 2016 08:28 am ET

VBI Vaccines Reports Rapid Seroprotection Results from an Interim Analysis of a Phase IV Postmarketing Study of its Sci-B-Vac(TM) Hepatitis B Vaccine

VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) ("VBI") today reported interim results from an ongoing Phase IV postmarketing study to evaluate Sci-B-Vac™, VBI's licensed third-generation hepatitis B vaccine, in healthy adults. In its...

Nov 10, 2016 08:30 am ET

VBI Vaccines to Present at the Society of Neuro-Oncology Annual Meeting

VBI Vaccines Inc. (NASDAQ: VBIV)(TSX: VBV) ("VBI") is scheduled to present at the Society of Neuro-Oncology Annual Meeting on Friday, November 18, 2016 at 7:00 PM MST (5:00 PM EST). The event is being held at the Scottsdale Fairmont Princess Hotel in Scottsdale, AZ.

Nov 10, 2016 08:28 am ET

VBI Vaccines to Present at the Society of Neuro-Oncology Annual Meeting

VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) ("VBI") is scheduled to present at the Society of Neuro-Oncology Annual Meeting on Friday, November 18, 2016 at 7:00 PM MST (5:00 PM EST). The event is being held at the Scottsdale Fairmont Princess Hotel in...

Oct 27, 2016 08:30 am ET

VBI Vaccines to Present Zika Vaccine Program Poster at the Keystone Symposia on Translational Vaccinology for Global Health

VBI Vaccines Inc. (NASDAQ: VBIV)(TSX: VBV) ("VBI") is scheduled to present at the Keystone Symposia on Translational Vaccinology for Global Health on Thursday, October 27, 2016 at 7:00 PM BST (2:00 PM ET). The event is being held at the Park Plaza Riverbank London in the United Kingdom.

Oct 27, 2016 08:28 am ET

VBI Vaccines to Present Zika Vaccine Program Poster at the Keystone Symposia on Translational Vaccinology for Global Health

VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) ("VBI") is scheduled to present at the Keystone Symposia on Translational Vaccinology for Global Health on Thursday, October 27, 2016 at 7:00 PM BST (2:00 PM ET). The event is being held at the Park Plaza...

Oct 11, 2016 08:30 am ET

VBI Vaccines Completes Pre-IND Meeting for its Glioblastoma Immunotherapy Candidate

VBI Vaccines Inc. (NASDAQ: VBIV) (TSX: VBV) ("VBI") today announced that it has completed a pre-IND meeting with the U.S. Food and Drug Administration ("FDA") to discuss the development plan for VBI-1901, VBI's glioblastoma multiforme ("Glioblastoma" or "GBM") immunotherapy candidate.

Oct 11, 2016 08:28 am ET

VBI Vaccines Completes Pre-IND Meeting for its Glioblastoma Immunotherapy Candidate

VBI Vaccines Inc. (NASDAQ:VBIV) (TSX:VBV) ("VBI") today announced that it has completed a pre-IND meeting with the U.S. Food and Drug Administration ("FDA") to discuss the development plan for VBI-1901, VBI's glioblastoma multiforme ("Glioblastoma"...

Oct 05, 2016 08:30 am ET

VBI Vaccines to Present at the World Vaccine Congress Europe

VBI Vaccines Inc. (NASDAQ: VBIV)(TSX: VBV) ("VBI") is scheduled to present at the 17th Annual World Vaccine Congress Europe on Monday, October 10, 2016 at 3:45 PM CEST (9:45 AM ET). The event is being held at the Fairmont Rey Juan Carlos I in Barcelona, Spain.

Oct 05, 2016 08:28 am ET

VBI Vaccines to Present at the World Vaccine Congress Europe

VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) ("VBI") is scheduled to present at the 17th Annual World Vaccine Congress Europe on Monday, October 10, 2016 at 3:45 PM CEST (9:45 AM ET). The event is being held at the Fairmont Rey Juan Carlos I in...

Sep 26, 2016 04:30 pm ET

VBI Vaccines Announces Results of Annual General and Special Meeting

VBI Vaccines Inc. (NASDAQ: VBIV)(TSX: VBV) ("VBI") today announced the voting results from its annual general and special meeting (the "Meeting") held on September 23, 2016.

Sep 26, 2016 04:28 pm ET

VBI Vaccines Announces Results of Annual General and Special Meeting

VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) ("VBI") today announced the voting results from its annual general and special meeting (the "Meeting") held on September 23, 2016. A total of 26,558,396 shares were represented at the Meeting, being...

Sep 26, 2016 08:30 am ET

VBI Vaccines to Present at the Ladenburg Thalmann Healthcare Conference

VBI Vaccines Inc. (NASDAQ: VBIV)(TSX: VBV) ("VBI") is scheduled to present at the Ladenburg Thalmann Healthcare Conference on Tuesday, September 27, 2016 at 10:00 AM ET. The event is being held at the Sofitel New York Hotel in New York, NY.

Sep 26, 2016 08:28 am ET

VBI Vaccines to Present at the Ladenburg Thalmann Healthcare Conference

VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) ("VBI") is scheduled to present at the Ladenburg Thalmann Healthcare Conference on Tuesday, September 27, 2016 at 10:00 AM ET. The event is being held at the Sofitel New York Hotel in New York, NY....

Sep 20, 2016 08:30 am ET

VBI Vaccines Completes Enrollment of Participants in the Phase I Clinical Trial of Its Preventative Cytomegalovirus Vaccine Candidate

VBI Vaccines Inc. (NASDAQ: VBIV)(TSX: VBV) ("VBI") today announced that it has completed enrollment and initial dosing of all participants in the Phase I clinical study to evaluate its preventative cytomegalovirus ("CMV") vaccine candidate.

Sep 20, 2016 08:28 am ET

VBI Vaccines Completes Enrollment of Participants in the Phase I Clinical Trial of Its Preventative Cytomegalovirus Vaccine Candidate

VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) ("VBI") today announced that it has completed enrollment and initial dosing of all participants in the Phase I clinical study to evaluate its preventative cytomegalovirus ("CMV") vaccine candidate....

Sep 07, 2016 08:30 am ET

VBI Vaccines to Present at the Rodman & Renshaw Annual Global Investment Conference

VBI Vaccines Inc. (NASDAQ: VBIV)(TSX: VBV) ("VBI") is scheduled to present at the Rodman & Renshaw 18th Annual Global Investment Conference on Tuesday, September 13, 2016 at 5:05 PM ET. The event is being held at the Lotte New York Palace Hotel in New York, NY.

Sep 07, 2016 08:28 am ET

VBI Vaccines to Present at the Rodman & Renshaw Annual Global Investment Conference

VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) ("VBI") is scheduled to present at the Rodman & Renshaw 18th Annual Global Investment Conference on Tuesday, September 13, 2016 at 5:05 PM ET. The event is being held at the Lotte New York Palace Hotel in...

Sep 01, 2016 08:30 am ET

VBI Vaccines to Present at the Vaccine Congress

VBI Vaccines Inc. (NASDAQ: VBIV)(TSX: VBV) ("VBI") is scheduled to present at the 10th Vaccine Congress on Monday, September 5, 2016 at 12:45 PM CEST (6:45 AM ET). The event is being held at the NH Grand Hotel Krasnapolsky in Amsterdam, the Netherlands.

Sep 01, 2016 08:28 am ET

VBI Vaccines to Present at the Vaccine Congress

VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) ("VBI") is scheduled to present at the 10th Vaccine Congress on Monday, September 5, 2016 at 12:45 PM CEST (6:45 AM ET). The event is being held at the NH Grand Hotel Krasnapolsky in Amsterdam, the...

Aug 29, 2016 08:30 am ET

VBI Vaccines to Present at the Immuno-Oncology Summit

VBI Vaccines Inc. (NASDAQ: VBIV)(TSX: VBV) ("VBI") is scheduled to present at the 4th Annual Immuno-Oncology Summit on Wednesday, August 31, 2016 at 11:15 AM ET. The event is being held at the Marriott Long Wharf Hotel in Boston, MA.

Aug 29, 2016 08:28 am ET

VBI Vaccines to Present at the Immuno-Oncology Summit

VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) ("VBI") is scheduled to present at the 4th Annual Immuno-Oncology Summit on Wednesday, August 31, 2016 at 11:15 AM ET. The event is being held at the Marriott Long Wharf Hotel in Boston, MA. During...

Aug 22, 2016 08:30 am ET

VBI Vaccines to Continue Enrolling Participants in the Phase I Trial of its Preventative Cytomegalovirus Vaccine Candidate Following Successful Data Safety Monitoring Board Review

VBI Vaccines Inc. (NASDAQ: VBIV) (TSX: VBV) ("VBI") today announced that, following a review of safety data from the limited safety immunization period, the Data Safety Monitoring Board ("DSMB") has no objection to VBI continuing with the enrollment of participants across all sites and dose groups in the Phase I clinical study to evaluate its preventative cytomegalovirus ("CMV") vaccine candidate.

Aug 22, 2016 08:28 am ET

VBI Vaccines to Continue Enrolling Participants in the Phase I Trial of its Preventative Cytomegalovirus Vaccine Candidate Following Successful Data Safety Monitoring Board Review

Jul 25, 2016 08:30 am ET

VBI Vaccines Appoints Dr. Francisco Diaz-Mitoma as Chief Medical Officer

VBI Vaccines Inc. (NASDAQ: VBIV)(TSX: VBV) ("VBI") is pleased to announce the appointment of Dr. Francisco Diaz-Mitoma, M.D., Ph.D., as Chief Medical Officer. In his new position, Dr. Diaz-Mitoma will oversee clinical development initiatives at VBI.

Jul 25, 2016 08:28 am ET

VBI Vaccines Appoints Dr. Francisco Diaz-Mitoma as Chief Medical Officer

VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) ("VBI") is pleased to announce the appointment of Dr. Francisco Diaz-Mitoma, M.D., Ph.D., as Chief Medical Officer. In his new position, Dr. Diaz-Mitoma will oversee clinical development initiatives at VBI....

Jul 19, 2016 08:30 am ET

VBI Vaccines Applies its eVLP Platform in the Development of a Novel Vaccine Candidate to Prevent Zika Virus

VBI Vaccines Inc. (NASDAQ: VBIV)(TSX: VBV) ("VBI") today announced that it has applied its clinical-stage eVLP Platform to the development of a novel vaccine candidate to prevent Zika virus ("Zika") infection.

Jul 19, 2016 08:28 am ET

VBI Vaccines Applies its eVLP Platform in the Development of a Novel Vaccine Candidate to Prevent Zika Virus

VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) ("VBI") today announced that it has applied its clinical-stage eVLP Platform to the development of a novel vaccine candidate to prevent Zika virus ("Zika") infection. "The alarming rise of Zika, and...

Jun 23, 2016 08:30 am ET

VBI Vaccines Begins Enrolling Patients in a Phase I Trial of its Preventative Cytomegalovirus Vaccine Candidate

VBI Vaccines Inc. (NASDAQ: VBIV)(TSX: VBV) ("VBI") has received a No Objection Letter from Health Canada, providing clearance to begin enrolling Canadian participants in a Phase I clinical study to evaluate VBI's preventative cytomegalovirus ("CMV") vaccine candidate in humans.

Jun 23, 2016 08:28 am ET

VBI Vaccines Begins Enrolling Patients in a Phase I Trial of its Preventative Cytomegalovirus Vaccine Candidate

VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) ("VBI") has received a No Objection Letter from Health Canada, providing clearance to begin enrolling Canadian participants in a Phase I clinical study to evaluate VBI's preventative cytomegalovirus...

Jun 21, 2016 08:30 am ET

VBI Vaccines Announces Closing of $13.6 Million Private Placement

VBI Vaccines (NASDAQ: VBIV)(TSX: VBV) ("VBI"), today announced the closing of an equity private placement financing led by OPKO Health (NYSE: OPK) and Perceptive Advisors, with participation by ARCH Venture Partners. In accordance with Toronto Stock Exchange (TSX) regulations, aggregate participation by certain current investors was limited to 10% of the issued and outstanding common shares in any given 6-month period. As a result, these current investors in VBI participated to their maximum possible allocation.

Jun 21, 2016 08:28 am ET

VBI Vaccines Announces Closing of $13.6 Million Private Placement

Jun 17, 2016 08:30 am ET

VBI Vaccines to Present at the Virus-Like Particle and Nano-Particle Vaccines Conference

VBI Vaccines Inc. (NASDAQ: VBIV)(TSX: VBV) ("VBI") is scheduled to present at the Virus-Like Particle and Nano-Particle Vaccines ("VLPNPV") Conference on Friday, June 24 at 9:00 AM CEDT (3:00 AM ET). The event is being held at the Leiden University Medical Center in the Netherlands.

Jun 17, 2016 08:28 am ET

VBI Vaccines to Present at the Virus-Like Particle and Nano-Particle Vaccines Conference

VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) ("VBI") is scheduled to present at the Virus-Like Particle and Nano-Particle Vaccines ("VLPNPV") Conference on Friday, June 24 at 9:00 AM CEDT (3:00 AM ET). The event is being held at the Leiden University...

Jun 16, 2016 08:30 am ET

VBI Vaccines Announces Medulloblastoma Immunotherapy Program

VBI Vaccines Inc. (NASDAQ: VBIV)(TSX: VBV) ("VBI") today announced that it is developing a novel therapeutic vaccine candidate for medulloblastoma. The Meghan Rose Bradley Foundation, a pediatric brain cancer advocacy organization, has provided a grant to perform initial research to evaluate VBI's immunotherapy candidate in ex vivo studies using medulloblastoma patient samples.

Jun 16, 2016 08:28 am ET

Ad blocking detected

VBI Vaccines Inc. (T:VBV)

Business Focus: Biotechnology & Medical Research (NEC)